Rapamycin, a drug which inhibits mTOR signaling, has been found to significantly reduce the load of Aβ and slow or halt the progression of symptoms in an AD mouse model and has been suggested as a clinical treatment for AD patients (Spilman et al., 2010; Kaeberlein and Galvan, 2019). This evidence concerns the gene MTOR and Alzheimer disease.